NRx Chairman Dr. Javitt to Present at the Ketamine 2024 Conference UK
Ketamine ER by Douglas Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
TORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the œCompany or œPharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to...
Enforcement Report - Week of May 24, 2023
TORONTO--(BUSINESS WIRE)--Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced it has received approval from Health Canada to import ketamine solution for injection pursuant to Health Canada’s exceptional importation and sale guidelines. Juno has procured 25,000 units for immediate release, providing a 6-week supply to the entirety of the Canadian market.
Fresenius' Generic Ketamine Hydrochloride Receives Approval in the U.S.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced top-line results of its Phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the company intends to request a meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of this study and the continued clinical development of MELT-300.
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that a poster presentation of the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at Neuroscience 2022 by the Society for Neuroscience being held November 12-16, 2022, at the San Diego Convention Center in San Diego, California. In addition, the Company has engaged the FDA to establish the next steps for a planned Phase 3 clinical study to allow for the Company’s proprietary ketamine intravenous product, KETARX™, approval for Parkinson’s disease under the 505(b)(2) regulatory pathway.
Each of these new therapies has a proposed rationale for its utility. Ketamine and its molecular sister esketamine increase the effect of glutamate, the most widespread natural chemical stimulant in the brain. Cannabis binds to a series of receptors for its active ingredients, tetrahydrocannabinol and cannabidiol existent in the brain.